483 related articles for article (PubMed ID: 8968694)
1. Hepatotoxicity of antitubercular treatments. Rationale for monitoring liver status.
Durand F; Jebrak G; Pessayre D; Fournier M; Bernuau J
Drug Saf; 1996 Dec; 15(6):394-405. PubMed ID: 8968694
[TBL] [Abstract][Full Text] [Related]
2. [Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients].
Wada M
Kekkaku; 2001 Jan; 76(1):33-43. PubMed ID: 11211781
[TBL] [Abstract][Full Text] [Related]
3. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
API Consensus Expert Committee
J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
[TBL] [Abstract][Full Text] [Related]
4. Hepatotoxicity of pyrazinamide: cohort and case-control analyses.
Chang KC; Leung CC; Yew WW; Lau TY; Tam CM
Am J Respir Crit Care Med; 2008 Jun; 177(12):1391-6. PubMed ID: 18388355
[TBL] [Abstract][Full Text] [Related]
5. [The effectiveness of pyrazinamide-containing six-month short course chemotherapy].
Wada M
Kekkaku; 2000 Nov; 75(11):665-73. PubMed ID: 11140090
[TBL] [Abstract][Full Text] [Related]
6. Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis: improved completion rates but more hepatotoxicity.
McNeill L; Allen M; Estrada C; Cook P
Chest; 2003 Jan; 123(1):102-6. PubMed ID: 12527609
[TBL] [Abstract][Full Text] [Related]
7. Controlled trial of 4 three-times-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis. Second report: the results up to 24 months. Hong Kong Chest Service/British Medical Research Council.
Tubercle; 1982 Jun; 63(2):89-98. PubMed ID: 6758252
[TBL] [Abstract][Full Text] [Related]
8. Hepatic toxicity in South Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampicin and pyrazinamide.
Parthasarathy R; Sarma GR; Janardhanam B; Ramachandran P; Santha T; Sivasubramanian S; Somasundaram PR; Tripathy SP
Tubercle; 1986 Jun; 67(2):99-108. PubMed ID: 3775870
[TBL] [Abstract][Full Text] [Related]
9. Hepatotoxicity due to rifampicin, isoniazid and pyrazinamide in patients with tuberculosis: is anti-HCV a risk factor?
Nader LA; de Mattos AA; Picon PD; Bassanesi SL; De Mattos AZ; Pineiro Rodriguez M
Ann Hepatol; 2010; 9(1):70-4. PubMed ID: 20308724
[TBL] [Abstract][Full Text] [Related]
10. Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy.
Lee BH; Koh WJ; Choi MS; Suh GY; Chung MP; Kim H; Kwon OJ
Chest; 2005 Apr; 127(4):1304-11. PubMed ID: 15821209
[TBL] [Abstract][Full Text] [Related]
11. [Hepatic functional changes induced by the combined use of isoniazid, pyrazinamide and rifampicin in the treatment of pulmonary tuberculosis].
de Souza AF; de Oliveira e Silva A; Baldi J; de Souza TN; Rizzo PM
Arq Gastroenterol; 1996; 33(4):194-200. PubMed ID: 9302332
[TBL] [Abstract][Full Text] [Related]
12. Safety of an ofloxacin-based antitubercular regimen for the treatment of tuberculosis in patients with underlying chronic liver disease: a preliminary report.
Saigal S; Agarwal SR; Nandeesh HP; Sarin SK
J Gastroenterol Hepatol; 2001 Sep; 16(9):1028-32. PubMed ID: 11595068
[TBL] [Abstract][Full Text] [Related]
13. [The adverse reactions of anti-tuberculosis drugs and its management].
Wada M
Nihon Rinsho; 1998 Dec; 56(12):3091-5. PubMed ID: 9883616
[TBL] [Abstract][Full Text] [Related]
14. Management of and risk factors related to hepatotoxicity during tuberculosis treatment.
Babalık A; Arda H; Bakırcı N; Ağca S; Oruç K; Kızıltaş S; Cetintaş G; Calışır HC
Tuberk Toraks; 2012; 60(2):136-44. PubMed ID: 22779934
[TBL] [Abstract][Full Text] [Related]
15. Treatment of lymph node tuberculosis--a randomized clinical trial of two 6-month regimens.
Jawahar MS; Rajaram K; Sivasubramanian S; Paramasivan CN; Chandrasekar K; Kamaludeen MN; Thirithuvathas AJ; Ananthalakshmi V; Prabhakar R
Trop Med Int Health; 2005 Nov; 10(11):1090-8. PubMed ID: 16262733
[TBL] [Abstract][Full Text] [Related]
16. Side-effects of drug regimens used in short-course chemotherapy for pulmonary tuberculosis. A controlled clinical study.
Zierski M; Bek E
Tubercle; 1980 Mar; 61(1):41-9. PubMed ID: 6989067
[TBL] [Abstract][Full Text] [Related]
17. Tuberculosis in neonates and infants: epidemiology, pathogenesis, clinical manifestations, diagnosis, and management issues.
Skevaki CL; Kafetzis DA
Paediatr Drugs; 2005; 7(4):219-34. PubMed ID: 16117559
[TBL] [Abstract][Full Text] [Related]
18. Safety and completion rate of short-course therapy for treatment of latent tuberculosis infection.
Cook PP; Maldonado RA; Yarnell CT; Holbert D
Clin Infect Dis; 2006 Aug; 43(3):271-5. PubMed ID: 16804838
[TBL] [Abstract][Full Text] [Related]
19. Hepatic enzyme abnormalities in children on triple therapy for tuberculosis.
Corrigan D; Paton J
Pediatr Pulmonol; 1999 Jan; 27(1):37-42. PubMed ID: 10023790
[TBL] [Abstract][Full Text] [Related]
20. Antituberculosis drugs and hepatotoxicity.
Yew WW; Leung CC
Respirology; 2006 Nov; 11(6):699-707. PubMed ID: 17052297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
